C07C 317/46
The carbon skeleton being further substituted by singly-bound oxygen atoms
Official title: the carbon skeleton being further substituted by singly-bound oxygen atoms
C07C317/46 (The carbon skeleton being further substituted by singly-bound oxygen atoms) appears on 239 US grants and 201 published applications in this corpus.
Search patents in C07C- Granted patents
- 239
- Published applications
- 201
- Assignees
- 167
- Inventors
- 896
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 8 | 0 |
| 1992 | 5 | 0 |
| 1993 | 4 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 7 | 0 |
| 1997 | 4 | 0 |
| 1998 | 18 | 0 |
| 1999 | 9 | 0 |
| 2000 | 8 | 0 |
| 2001 | 14 | 3 |
| 2002 | 10 | 9 |
| 2003 | 6 | 10 |
| 2004 | 5 | 17 |
| 2005 | 4 | 9 |
| 2006 | 5 | 7 |
| 2007 | 11 | 12 |
| 2008 | 4 | 13 |
| 2009 | 15 | 16 |
| 2010 | 4 | 13 |
| 2011 | 6 | 7 |
| 2012 | 9 | 8 |
| 2013 | 9 | 9 |
| 2014 | 8 | 7 |
| 2015 | 6 | 5 |
| 2016 | 7 | 14 |
| 2017 | 8 | 9 |
| 2018 | 8 | 8 |
| 2019 | 3 | 5 |
| 2020 | 7 | 5 |
| 2021 | 2 | 3 |
| 2022 | 2 | 3 |
| 2023 | 1 | 4 |
| 2024 | 1 | 0 |
| 2025 | 1 | 4 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Thyromimetics20 Jan 2026US 12,528,761 B2Autobahn Therapeutics, Inc.
- Selective androgen receptor degrader (SARD) ligands and methods of use thereof4 Feb 2025US 12,215,086 B2University of Tennessee Research Foundation
- Aryl ethers and uses thereof30 Apr 2024US RE49,948 E1Peloton Therapeutics, Inc.
- Thyromimetics6 Jun 2023US 11,667,606 B2Autobahn Therapeutics, Inc.
- ROR gamma (RORγ) modulators12 Apr 2022US 11,299,456 B2Lead Pharma Holding B.V.
- Preparation method for 1-[2-chloro-3-(bromomethyl)-4-(methylsulfonyl)phenyl]ethanone and the use of same1 Oct 2026US 2026/0297023 A1Nutrichem Company Limited
- Aromatic compound and use thereof25 Dec 2025US 2025/0388560 A1Hitgen Inc.
- Rxfp1 agonists28 Aug 2025US 2025/0268903 A1Bristol-Myers Squibb Company
- Aryl cyclohexanedione derivative or salt thereof, pest control agent containing same, and method for use thereof17 Apr 2025US 2025/0122147 A1Adeka Corporation
- Naphthalene and quinoline analogs as rxfp1 agonists27 Mar 2025US 2025/0100960 A1Bristol-Myers Squibb Company
Most cited
By later US patents
- Methods and compositions for inhibiting cell proliferative disorders109US 5,789,427 ASugen, Inc. · 1998
- FLK-1 is a receptor for vascular endothelial growth factor90US 5,851,999 AMax-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V. · 1998
- Benzene compound having 2 or more substituents87US 7,923,573 B2Daiichi Sankyo Company, Limited · 2011
- Methods and compositions for inhibiting cell proliferative disorders85US 5,773,476 ASugen, Inc. · 1998
- Quinazoline compounds and compositions thereof for the treatment of disease84US 5,792,771 ASugen, Inc. · 1998